1. Introduction {#s0005}
===============

Neuroimaging research in the field of dementia focuses on the impact of behavioral, neuropsychological, genetic and demographic factors on brain atrophy associated with transition from healthy aging through mild cognitive impairment (MCI) and further to Alzheimer\'s disease (AD) ([@bb0025; @bb0080; @bb0095; @bb0100; @bb0120; @bb0125; @bb0135; @bb0180; @bb0185; @bb0280]). We face a steadily increasing number of structural magnetic resonance imaging (sMRI, ([@bb0050; @bb0215])) and \[18F\]fluorodeoxyglucose positron emission tomography (FDG-PET, ([@bb0140; @bb0145; @bb0255])) studies showing high sensitivity to the disease process when used separately ([@bb0005; @bb0010; @bb0170; @bb0175; @bb0210; @bb0215; @bb0270]) and a gain in diagnostic accuracy when used together in a multimodal approach ([@bb0065; @bb0085]).

A viable way of understanding pathophysiology and further improving diagnostic accuracy in MCI and AD is the integration of previous knowledge about characteristic features of progression from a healthy state to AD. However, the straightforward interpretation of such an integrative approach could be limited by either systematic differences in demographic and cognitive abilities within patients and healthy controls or the use of particular image data processing algorithms ([@bb0040; @bb0060; @bb0190]). One such demographic factor that has been shown to have a strong differential impact on disease progression is age. Previous studies have indicated that early-onset (age \< 65 years) and late-onset (age ≥ 65 years) AD patients show a differential pathology in MRI and FDG-PET ([@bb0030; @bb0115; @bb0165; @bb0195; @bb0200; @bb0240; @bb0260]). Nonetheless, the interpretation of these differences is still controversial as the differences might be explained by a differential age specific baseline resulting from comparison of early- and late-onset AD patients to different age-matched control group or to each other, by differential underlying pathology or by an interaction of age and disease related brain network changes. Also the link between FDG-PET and MRI and the current (as indicated by symptom severity) and future cognitive state (as indicated by future cognitive decline) is a matter of debate. Both imaging modalities have been reported to correlate with both current symptom severity and the future cognitive decline ([@bb0035; @bb0055; @bb0075; @bb0105; @bb0285; @bb0290]). These findings on the other side are not fully compatible with the currently widely accepted model of progression of both imaging markers in AD suggesting a differential time-line of progression with FDG-PET showing first a rapid decline and atrophy developing rather later in the progression from healthy aging to MCI and further to AD ([@bb0170]). An accurate estimation of the unique impact of these specific factors and their interaction on the progression of MCI or AD is crucial to integrate findings across different studies. Longitudinal studies offer a potential solution; although they are logistically difficult to carry out and lack complete control for all possible confounds within a cohort ([@bb0045; @bb0055; @bb0185]).

The aim of this study is to disentangle the effect of age, symptom severity as measured by Mini Mental State Examination (MMSE, ([@bb0090])) and time to conversion (TTC) on changes in two prominent imaging biomarkers of AD---glucose metabolism and brain atrophy pattern. Therefore, we systematically investigate the effect of the factors age, symptom severity and TTC (in MCI patients) on brain pathology observed in both imaging modalities using the same group of control subjects whilst accounting for the effect of healthy aging using a recently proposed approach ([@bb0070]). The use of the same group of patients for investigation of the effects of different variables of interest is expected to reduce potential confounding effects in other uncontrolled factors. By additionally accounting for the variance explained by healthy aging we target the question on how much AD related pathology is required at different ages to induce the same level of cognitive impairment.

Given the fact that age interacts with AD-specific atrophy patterns ([@bb0110; @bb0135]), we expected that younger MCI converters (cMCI) and younger AD patients would show a more extensive pattern of atrophy and glucose hypometabolism than older patients with similar symptom severity. According to a recent model of MCI progression characterised by rapid reduction in glucose metabolism followed by brain atrophy in much later stages of disease progression ([@bb0170]), we hypothesized that cMCI would initially show a more extensive decrease in glucose utilisation compared to the amount of atrophy associated with closeness to conversion. Keeping in mind that both FDG-PET and sMRI correlate with cognitive decline ([@bb0105; @bb0155]), we hypothesized that by accounting for partial volume effects (PVE) in FDG-PET, changes in symptom severity would be more strongly linked to gray matter (GM) volume reductions than to glucose hypometabolism during progression from MCI to AD.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

To evaluate the effect of age, symptom severity and TTC on differences in FDG-PET and sMRI, we used multicenter sMRI and FDG-PET data of AD patients (n = 80), cMCI (n = 65), MCI non-converters (ncMCI, n = 64) and healthy control subjects (n = 79) ([Table 1](#t0005){ref-type="table"}). The mean follow-up ± standard deviation for ncMCI was 26.8 ± 9.1 month, for cMCI 28.1 ± 8.0 month, for AD 19.8 ± 7.7 month and for the control group 30.5 ± 8.3 month. All data were extracted from the Alzheimer\'s disease Neuroimaging Initiative (ADNI) database ([www.adni-info.org](http://www.adni-info.org){#ir0035}). Data were selected for availability of FDG-PET (50% of the ADNI cohort). Additionally, selection criteria were, if possible, matching for age and gender. Exclusion criteria for the current study were reported quality problems in imaging acquisition (e.g. moderate to severe motion artifacts). The cMCI group consisted of patients who converted to AD within 36 months of follow-up. Diagnosis of AD patients was based on NINCDS/ARDRA criteria ([@bb0235]). Only stable MCI according to all available follow-up information were included in the ncMCI group. Similarly, group definition for all other groups comprised all available follow-up information, e.g. only subjects without reported conversion to MCI or AD in the available follow-up were included in the control group. Exclusion criteria for the ADNI data were the presence of any significant neurological disease other than AD, history of head trauma followed by persistent neurological deficits or structural brain abnormalities, psychotic features, agitation or behavioral problems within the previous three months or history of alcohol or substance abuse. A detailed description of the ADNI inclusion and exclusion criteria can be found under the following url: <http://www.adni-info.org/pdfs/adni_protocol_9_19_08.pdf>. Additionally, a list of subjects included in our study is provided in [Supplement 1](#ec0005){ref-type="supplementary-material"}. For each subject, only data from the first study time-point were used for further analysis. The study was conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants before protocol-specific procedures were performed.

To evaluate the effect of age, symptom severity and TTC on differences in FDG-PET and sMRI, we used multicenter sMRI and FDG-PET data of AD patients (n = 80), cMCI (n = 65), MCI non-converters (ncMCI, n = 64) and healthy control subjects (n = 79) ([Table 1](#t0005){ref-type="table"}). The mean follow-up ± standard deviation for ncMCI was 26.8 ± 9.1 month, for cMCI 28.1 ± 8.0 month, for AD 19.8 ± 7.7 month and for the control group 30.5 ± 8.3 month. All data were extracted from the Alzheimer\'s disease Neuroimaging Initiative (ADNI) database ([www.adni-info.org](http://www.adni-info.org){#ir0037}). Data were selected for availability of FDG-PET (50% of the ADNI cohort). Additionally, selection criteria were, if possible, matching for age and gender. Exclusion criteria for the current study were reported quality problems in imaging acquisition (e.g. moderate to severe motion artifacts). The cMCI group consisted of patients who converted to AD within 36 months of follow-up. Diagnosis of AD patients was based on NINCDS/ARDRA criteria ([@bb0235]). Only stable MCI according to all available follow-up information were included in the ncMCI group. Similarly, group definition for all other groups comprised all available follow-up information, e.g. only subjects without reported conversion to MCI or AD in the available follow-up were included in the control group. Exclusion criteria for the ADNI data were the presence of any significant neurological disease other than AD, history of head trauma followed by persistent neurological deficits or structural brain abnormalities, psychotic features, agitation or behavioral problems within the previous three months or history of alcohol or substance abuse. A detailed description of the ADNI inclusion and exclusion criteria can be found under the following url: <http://www.adni-info.org/pdfs/adni_protocol_9_19_08.pdf>. Additionally, a list of subjects included in our study is provided in Supplement 1. For each subject, only data from the first study time-point were used for further analysis. The study was conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants before protocol-specific procedures were performed.

2.2. MRI data {#s0020}
-------------

The MRI dataset included standard T1-weighted images obtained with different 1.5 T scanner types using a 3D MP-RAGE sequence varying in TR and TE with an in-plane resolution of 1.25 × 1.25 mm and 1.2 mm slice thickness. All images were preprocessed as described on the ADNI website (<http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml>) including distortion and B1 non-uniformity corrections.

2.3. FDG-PET data {#s0025}
-----------------

FDG-PET scanning at different PET-scanner types was performed using one of the following three protocols: 1) dynamic: a 30 min six frame acquisition (6 five-minute frames), with scanning from 30 to 60 min post FDG injection; 2) static: a single-frame, 30 min acquisition with scanning 30--60 min post injection; and 3) quantitative: a 60 min dynamic protocol consisting of 33 frames, with scanning beginning at injection and continuing for 60 min. Images also differed in resolution, orientation, voxel and image dimensions and count statistics. The mean images of realigned frames from 30 to 60 min post injection were used for further analysis.

2.4. MRI pre-processing {#s0030}
-----------------------

All image-processing steps were carried out using the SPM5 software package (Wellcome Trust Centre for Neuroimaging: <http://www.fil.ion.ucl.ac.uk/spm/>) implemented in Matlab 7.7 (MathWorks Inc., Sherborn, MA). For common pre-processing sMRI and FDG-PET data we applied the same preprocessing procedure as described in detail in Dukart et al. ([@bb0065]). In this procedure, structural MRI data were first interpolated to an isotropic resolution of 1 × 1 × 1 mm^3^, bias corrected for inhomogeneity artifacts and segmented into grey matter, white matter and cerebrospinal fluid (only the grey matter segments were used for further analyses). The segmented grey matter images were spatially normalized to a study specific template created from all subjects using a diffeomorphic registration algorithm---DARTEL ([@bb0020]). In this step, the images were modulated using Jacobian determinants to preserve the total amount of signal from each region. The obtained grey matter volume images were smoothed with a Gaussian kernel of 12 mm full width at half maximum and masked using a grey matter mask created by thresholding the first and the last DARTEL template by 0.2 to avoid big edge effects.

2.5. FDG-PET pre-processing {#s0035}
---------------------------

FDG-PET data were interpolated to an isotropic resolution of 1 × 1 × 1 mm^3^ and co-registered to the corresponding sMRI scan of each subject using the co-registration function in SPM5. Further pre-processing included a convolution based PVE correction ([@bb0245; @bb0250]) of FDG-PET using sMRI data and subsequent masking of non-GM voxels. Spatial normalisation to a study specific template was performed using flow-fields obtained from sMRI data ([@bb0020]). As for sMRI a smoothing kernel of 12 mm full width at half maximum was applied to all FDG-PET data. The obtained FDG-PET and grey matter volume images had a very similar effective smoothness as indicated by subsequent SPM smoothness estimation during statistical analyses. FDG-PET data were intensity normalized to the cerebellar mean glucose uptake and masked using a grey matter mask to avoid big edge effects. The cerebellar region was chosen for intensity normalisation of FDG-PET as it has been shown to be a region of choice for intensity normalisation which is unaffected in healthy ageing and early stages of AD when correcting for PVE caused by atrophy ([@bb0060; @bb0220]).

2.6. Correction for age effects {#s0040}
-------------------------------

To remove the effect of healthy aging on glucose utilisation and regional grey matter volumes we first computed voxel-wise linear regressions only in control subjects and separately for both imaging modalities. In a second step the beta coefficients obtained from the voxel-wise linear regressions are applied to remove the variance explained by healthy ageing in patients\' and control subjects\' imaging data ([@bb0070]).

2.7. Statistical analysis of imaging data {#s0045}
-----------------------------------------

All statistical analyses of imaging data were carried out within the SPM5 framework. To investigate the effect of age on differences observed in FDG-PET and MRI in MCI and AD, the entire groups of AD, cMCI or ncMCI subjects were split based on age, symptom severity (MMSE score) or TTC (only for MCI converters) into 3 equally sized subgroups ([Tables 2, 3, 4](#t0010 t0015 t0020){ref-type="table"}) matching for the remaining one (or two for cMCI) variables. For example for the subdivision of the AD group by age the 80 AD subjects were sorted in an ascending order by age and then divided into three equally sized biggest possible subgroups (for AD 26 subjects per group: 26 ∗ 3 = 78) and leaving the remaining subjects for potential matching. Analyses of variance and if significant subsequent post-hoc t-tests were then computed to evaluate the subgroups for potential differences in variables of no-interest for the particular comparison (e.g. for age: MMSE (for cMCI also for TTC) and vice versa). If one of the tests indicated significant differences between the subgroups (e.g. significantly lower MMSE scores in younger AD), subjects with the extreme values in the corresponding group (in this case low MMSE scores) were replaced by some of the subjects left for matching and showing similar age values but higher MMSE scores. The statistical tests were then recomputed. If a test again revealed significant differences the subgroup size was reduced by removing from each subgroup one subject showing "extreme" relative values as compared to the mean of the subgroup in the significant variable of no interest. This procedure of replacing subjects or removing one subject from each subgroup was then repeated until matching in variables of no interest was achieved for each group and each subgroup splitting. FDG-PET and voxel-based morphometry (VBM) data of each subgroup were compared separately with the entire group of control subjects. Additionally, subgroups were matched for gender. There were no significant differences in the distribution of the FDG-PET protocols between the obtained subgroups.

All subgroup comparisons of AD, cMCI and ncMCI subjects with healthy controls were performed using a full factorial analysis of variance (ANOVA) design controlling for gender and total intracranial volume (for VBM). Total intracranial volume was calculated by counting all voxels in a sum image of grey matter, white matter and cerebrospinal fluid probability maps of each subject exceeding an absolute threshold of 0.2. This volume measurement was then recomputed into litres. In this, the three clinical subgroups (depending on split for age, symptom severity or TTC \[only for cMCI\]) and the control group were entered as independent factors. T-contrasts were used to evaluate differences between subgroups and control subjects. In contrast to classical parametric analyses, subgroup comparisons also provide the possibility to detect more complex relationships between age, symptom severity and TTC and differences observed in both imaging modalities. Such a complex relationship would be for example an increase in glucose hypometabolism only in middle-aged but not in younger or older AD patients. This kind of u-shaped relationships would not be detected by a regression analysis. A significance threshold of p \< 0.001 uncorrected at voxel-level and p \< 0.05 FWE-corrected for multiple comparisons at cluster level accounting for non-stationary smoothness in imaging data (as suggested for voxel-based morphometry data, Worsley et al., 1999; [@bb0150]) was used for all imaging contrasts. This approach has been explicitly suggested for VBM analyses. It is based on the random field theory and is determining for any chosen voxel-based statistical threshold a corresponding cluster extent threshold which each cluster has to exceed taking into account i) the voxel-wise statistical threshold, ii) the smoothness of the data and iii) the total amount of comparisons.

As in our study we further aimed to investigate differences in the extent of atrophy and glucose hypometabolism related to age, symptom severity and TTC in the subgroups, the extents of detected differences within each modality between different conditions and between the modalities for each condition were compared to each other using two proportions z-tests. Thereby the total amount of detected significant voxels for each comparison was expressed as a proportion relative to the total amount of voxels within the statistical mask. Further, as the difference in proportions of significant voxels is highly dependent on the chosen significance threshold (e.g. at a high threshold the same difference in cluster extent is less likely than at a lower threshold) and on data smoothness, the sample size was calculated as the total amount of tested voxels scaled by a factor calculated as the number of expected clusters times number of expected voxels per cluster. This information about number and extent of expected clusters is provided within the SPM software in the statistical evaluation of each contrast and is based on estimates of data smoothness and the chosen statistical threshold. For these comparisons a statistical threshold of p \< .05 Bonferroni corrected for the total amount of comparisons within each group was chosen.

2.8. Parametric analyses {#s0050}
------------------------

To additionally evaluate parametric differences related to age, symptom severity and TTC in FDG-PET and sMRI we performed three regression analyses for each of the modalities using either only AD, cMCI or ncMCI subjects. Age, gender and MMSE were included in all regression analyses with additional inclusion of TTC for the cMCI group. For all sMRI regression analyses total intracranial volume was included in the design matrix. Correlations of imaging data with age and MMSE were evaluated for all clinical groups. In addition, correlations with TTC were calculated for cMCI.

A significance threshold of p \< 0.001 uncorrected at voxel-level and p \< 0.05 FWE-corrected for non-stationarity of smoothness at cluster level was used ([@bb0150]).

2.9. Statistical analysis of behavioral data {#s0055}
--------------------------------------------

We performed ANOVAs for group comparisons for age and MMSE in the entire dataset and for all subgroups ([Tables 1, 2, 3](#t0005 t0010 t0015){ref-type="table"}). cMCI subgroups were additionally compared to each other for TTC. If an ANOVA revealed a significant between-group effect, a Bonferroni *t*-test was calculated with a significance threshold of p \< .05 (corrected for multiple comparisons, two-tailed). Group differences regarding sex were evaluated using a chi-square test for independent samples. The statistical analyses were performed with the commercial software package SPSS 17.0 (<http://www.spss.com/statistics/>). Additionally, we calculated correlations between all variables of interest for each clinical group separately with a significance threshold of p \< .05 (Bonferroni corrected for multiple comparisons, where deemed appropriate).

3. Results {#s0060}
==========

3.1. Imaging results {#s0065}
--------------------

### 3.1.1. Age {#s0070}

In young AD patients relative GM volume loss affected almost the whole cortex, sparing only sensorimotor and occipital regions ([Fig. 1](#f0005){ref-type="fig"}). In subcortical areas, both thalami were also atrophic. In middle-aged AD patients GM atrophy extended bilaterally to hippocampus, thalamus, cerebellum, cingulate, precuneate, parietal, temporal, occipital, frontal and insular cortices and to right putamen. In older AD patients we observed atrophy in bilateral hippocampi, thalami, temporal, temporo-parietal, sensorimotor and right occipital regions. In young AD patients glucose hypometabolism was observed in bilateral temporo-parietal, precuneus, posterior cingulate, lateral frontal, medial frontal and posterior thalamic regions. Glucose hypometabolism in middle-aged AD patients was restricted to bilateral temporo-parietal, right frontal, bilateral posterior cingulate regions and precuneus and in older patients to bilateral precuneus and to the right parietal cortex.

Young cMCI showed atrophy in bilateral hippocampal, precuneate, posterior cingulate, left parietal and right temporal cortices ([Fig. 1](#f0005){ref-type="fig"}). Middle-aged cMCI showed a very similar but more widespread pattern of atrophy additionally involving the right insula and both anterior thalami. In older cMCI, the most widespread atrophy was found that involved bilateral parietal, temporal and frontal cortices, the thalamus and the hippocampus. In contrast, glucose utilisation was most strongly reduced in young MCI converters, involving medial and lateral frontal, temporal, parietal and insular cortices, the cingulum, basal ganglia, thalamus and hippocampus. Both middle-aged and old cMCI showed glucose hypometabolism in precuneate and temporo-parietal regions. Additionally, older cMCI had reduced glucose metabolism in medial and lateral frontal cortical regions.

There was no significant atrophy in any of the ncMCI groups. Glucose utilisation was reduced in younger ncMCI in precuneate, temporal, parietal, lateral and medial frontal, hippocampal and thalamic regions. Middle-aged ncMCI showed decreased glucose metabolism in the right polar frontal cortex. No hypometabolism was observed in older ncMCI.

### 3.1.2. Symptom severity {#s0075}

In mild AD, atrophy was mainly restricted to precuneus, posterior cingulate, hippocampal, anterior thalamic, insular, lateral frontal, temporal and parietal regions. In contrast, in the moderately impaired AD group, atrophy was more extensive in parietal and temporal cortices and additionally involved orbito-frontal regions. In the more severe AD group, atrophy involved almost all cortical and subcortical structures, sparing only some motor regions and most parts of the cerebellum. AD patients with mild symptom severity showed decreased glucose utilisation in precuneus, bilateral temporal and right parietal regions. In moderately and severely impaired AD patients, we detected impaired glucose utilisation in a bilateral network consisting of lateral frontal, temporo-parietal and precuneate regions.

In both mild and moderate cMCI, atrophy was restricted to bilateral hippocampal and right temporal regions. cMCI with lowest MMSE scores revealed a more wide-spread pattern of atrophy covering lateral and orbital frontal, parietal, temporal, insular and occipital cortices in the patient group. Further, in this group, atrophy was significant in precuneate, hippocampal and anterior thalamic regions. In all three groups of cMCI glucose hypometabolism extended to temporo-parietal, lateral and medial frontal regions and precuneus. Additionally, cMCI with moderate symptom severity showed reduced glucose metabolism in both thalami and right caudate nuclei. Further, in cMCI with comparably mild symptom severity, we observed reduced glucose utilisation in orbito-frontal and insular cortices.

In ncMCI, only the group with the lowest MMSE showed significant atrophy in the right hippocampus whilst glucose hypometabolism was restricted to right precuneus and parietal regions ([Fig. 2](#f0010){ref-type="fig"}).

### 3.1.3. Time to conversion (TTC) {#s0080}

In the cMCI group converting to AD 24 months after initial presentation, GM atrophy was observed in hippocampal, anterior thalamic and right temporal regions ([Fig. 3](#f0015){ref-type="fig"}). In cMCI with a TTC of 18 months, GM atrophy was only detected in bilateral hippocampus. In the cMCI group converting to AD in 12 months, atrophy was restricted to bilateral hippocampus and to right temporo-parietal and temporal cortices. In cMCI with a TTC of 24 months glucose utilisation reductions were restricted to right temporo-parietal, right temporal and bilateral precuneate regions. In the cMCI group converting to AD 18 months glucose hypometabolism was found in temporal, cingulate, lateral and medial frontal and parietal regions. Glucose utilisation reduction was even more prominent in the group converting to AD in 12 months, involving precuneate, parietal, temporal, lateral and medial frontal, cingulate and insular regions.

3.2. Parametric results {#s0085}
-----------------------

In the AD group, we observed significant positive correlations of age with GM volume in bilateral occipital, parietal, temporal, frontal, posterior cingulate and cerebellar regions ([Fig. 4](#f0020){ref-type="fig"}). Given that we removed the voxel-wise effect of healthy aging on glucose utilisation and regional grey matter volumes in all patients based on estimates from healthy controls ([@bb0070]), positive correlations with age in AD indicate that less disease-related GM atrophy or glucose hypometabolism is required in higher age compared to lower age to induce the same symptom severity. Further significant correlations were observed in right insula and right dorsal nucleus caudatus. MMSE correlated with GM volume in bilateral parietal, temporal, frontal regions, posterior hippocampal and thalamic regions. In all clinical groups no further significant sMRI correlations were observed with any of the variables.

In AD significant positive correlations between age and glucose metabolism were observed in bilateral parietal and temporal cortices. In cMCI significant positive right-sided correlations with age were observed in parietal and temporal regions and in putamen. In ncMCI we observed significant positive correlations of age with glucose metabolism in right putamen, right parietal, temporal, premotor and insular regions and in left anterior cingulate cortex.

3.3. Behavioral results {#s0090}
-----------------------

In comparison of all groups of AD patients, cMCI, ncMCI and control subjects, there was no significant difference of age or sex \[*χ*^2^(3) = 3.2;p = .348\]. MMSE differed significantly between control subjects and patients \[Controls vs. MCI converters: t(142) = 6.5;p \< .001; Controls vs. ncMCI: t(103) = 4.2;p = .001; Controls vs. AD: t(141) = 16.6;p \< .001\]. There was a significant difference in MMSE between MCI and AD patients \[cMCI vs. AD: t(143) = 9.6;p \< .001; ncMCI vs. AD: t(142) = 11.8;p \< .001\]. The difference between cMCI and ncMCI was not significant \[t(127) = 2.3;p = .209\].

The subgroups of AD patients, cMCI and ncMCI, used for evaluation of age effects on FDG-PET and sMRI did not differ in symptom severity ([Tables 1, 2, 3](#t0005 t0010 t0015){ref-type="table"}) or in relation to sex. Of course, the between-group differences in age for the three subgroup comparisons were all highly significant (p \< .001). For AD, cMCI and ncMCI subgroups used for symptom severity evaluation, age ([Tables 2, 3, 4](#t0010 t0015 t0020){ref-type="table"}) and sex did not differ between subgroups. As expected, MMSE scores differed significantly (p \< .001) for these comparisons for AD, cMCI and ncMCI subgroups. Subgroups of cMCI for evaluation of TTC-related differences in FDG-PET and sMRI did not differ in age, sex or symptom severity.

Correlational analyses in the AD group revealed only very weak, insignificant correlations between age and symptom severity as measured by MMSE \[r = − .09;p = .444\]. In the cMCI group, the variables age, symptom severity and TTC were also only weakly but insignificantly correlated \[age and MMSE: r = − .24;p = .156; age and TTC: r = − .11;p = 1.0; MMSE and TTC: r = − .10;p = 1.0\]. Similarly, there was no significant correlation between age and MMSE in ncMCI \[r = − .21;p = .095\].

4. Discussion {#s0095}
=============

In this study we demonstrate and dissociate differential patterns of structural and metabolic brain differences related to age, symptom severity and disease progression in AD, cMCI and ncMCI subjects. An important aspect of our study is the focus on detection of the link between the spatial extent of AD related imaging pathology and age, symptom severity and TTC. This focus on spatial extents of pathology contrasts our study from previous research targeting rather the correlational link between these variables and the grade of glucose hypometabolism or atrophy at each particular voxel/region. Both types of relationships are rather independent. For example a reduction of neural function in a particular region under a particular threshold might have an impact on cognitive performance. However, any further increase in AD pathology in the very same region might not have any additional effect on cognition and would be therefore not detected by a correlational analysis. In this case only additional impairment of other brain regions would lead to further cognitive decline. By comparing all patient groups to the same control group and adjusting for healthy aging we further for the first time account for the potential confounding effect of the use of different control groups that was neglected in previous research.

The cMCI and ncMCI differ in the amount of glucose hypometabolism and brain atrophy explained by age and symptom severity with cMCI resembling AD patients. We confirm previous findings of a correlation between TTC and glucose metabolism as well as an inverse relationship between age increase and amount of atrophy and hypometabolism associated with a particular symptom severity in AD ([@bb0230; @bb0265]). Given that we account for differences associated with healthy aging, our findings of differences in the amount of glucose hypometabolism and atrophy in AD subgroups subdivided by age can be interpreted as pathological age-specific add-ons that relate to a degree of functional impairment.

Our study results in three important findings. Firstly, the differential age-related glucose hypometabolism and atrophy patterns between clinical groups have implications for the use of neuroimaging biomarkers for improving diagnostic accuracy and prediction of conversion to AD. While FDG-PET is the dominant biomarker in young cMCI and atrophy is mainly restricted to the hippocampus, the pattern observed in old cMCI is of prominent atrophy associated with equally marked glucose hypometabolism. This observation is consistent with a relative diagnostic superiority of FDG-PET compared to sMRI in younger patients with mild AD symptoms ([@bb0205; @bb0230]). The age-related differential pattern of abnormality discovered with FDG-PET and sMRI supports previous findings of better diagnostic performance with FDG-PET only in early-onset AD patients, but equivalent performance for the two in elderly patients ([@bb0230]).

The second finding concerns the relationship between symptom severity as measured by classical screening and the progression of changes in FDG-PET and sMRI. We demonstrate for cMCI and AD patients a strong link between symptom severity and the amount of atrophy, which is not evident in ncMCI. Interestingly, no such pattern was seen in glucose metabolism with any of the patient cohorts. This result indicates that changes measured by sMRI are more strongly related to the current symptom severity in AD patients.

A third, more surprising result was obtained when MCI converters were split by TTC. We expected that symptom severity and TTC would be strongly linked, as neuropsychological measurements are used to determine AD stage. However, the measurements are only weakly correlated, which suggests that different mechanisms produce current (as measured by MMSE) and future cognitive states (as measured by TTC). Thus, a comparison of TTC duration subgroups with healthy control subjects showed a TTC-dependant amount of glucose hypometabolism, but no relationship with the amount of atrophy. The link between FDG-PET measurements and subsequent cognitive decline is consistent with previous reports showing the superiority of FDG-PET compared to neuropsychological measurements for prediction of subsequent cognitive decline and conversion to AD in MCI patients ([@bb0015; @bb0035; @bb0160]).

The differential results for TTC and symptom severity-related differences observed with FDG-PET and sMRI cannot be explained by different pathologies or other factors because the cMCI subgroups came from splitting the same group of subjects.

The current view of the progression of FDG-PET and sMRI changes in AD is that functional abnormalities occur earlier than those with sMRI ([@bb0170]). Our results suggest a modification of the current model of biomarker changes related to progression from MCI to AD ([@bb0170]). Imaging abnormalities appear at an early stage in sMRI as well as FDG-PET; however, structural changes are restricted mainly to the hippocampus. In contrast, but consistent with the suggested model, glucose hypometabolism progresses rapidly in this early stage of AD. The model suggested by Jack et al. further implies that the magnitude of biomarker changes is equal in both FDG-PET and structural MRI data ([@bb0170]). The assumption behind this idea is that structural changes follow functional changes. In contrast, our data suggest that FDG-PET changes reach their peak already at the MCI stage ([Figs. 2 and 3](#f0010 f0015){ref-type="fig"}) and do not further increase but rather decrease (e.g. because the preserved tissue is maintaining its functional activity level) at later disease stages when adjusting for atrophy effects using PVE correction. In contrast, atrophy further increases at later AD stages in our study population and even extends to regions not showing any significant hypometabolism. For this reason we expect that if one would not use PVE correction, one would observe further reductions in glucose hypometabolism even in AD in agreement with [@bb0170].

Although the results of our study are relevant to improving understanding of progression from MCI to AD, some limitations need consideration to enable valid interpretation. Firstly, we used the same clinical groups to examine different variables of interest, with splitting into different subgroups depending on expression of the variables of interest. Therefore, the results may be confounded by between-group differences in uncontrolled factors such as functional asymmetries, intelligence quotient and other more specific cognitive domains associated with Alzheimer\'s disease. Such differences in uncontrolled factors might have contributed to the observed differences in the amount of atrophy and hypometabolism and shall be overcome in future large-scale longitudinal studies. Secondly, although subgroup comparisons for confounding variables were not significant in ANOVAs, they could have contributed to the differential results. We feel this is unlikely to have introduced any systematic bias, as the between-group differences were small and restricted to only one of the subgroups.

When removing the variance explained by healthy ageing in the imaging data we make the explicit assumption of linearity of age related differences in GM volume and glucose metabolism. This issue has been a major focus of several large scale volumetric and PET studies performed in the past two decades ([@bb0130; @bb0135; @bb0225; @bb0275]). All of these studies provided strong evidence that linear as compared to more complex models are sufficient to describe global and local atrophy and glucose metabolism reductions observed in the course of normal ageing (from the age of 20 to 100 years. Our assumption is therefore in line with previous research performed on that topic. Nonetheless, imprecisions of the applied voxel-wise healthy ageing models e.g. due to wrong linearity assumptions are a general possible confounding effect for studying age-specific differences in diseased populations. In this framework it is also important to note that age-related findings we report in our study only reflect cross-sectional differences in sMRI and FDG-PET between differently aged AD/MCI patient groups. They should therefore not be confused with within subject longitudinal changes related to AD progression.

A further limitation of our study is that a proportion of control subjects used in our study might have a preclinical AD pathology. The inclusion of such subjects could have lowered the effects observed in subgroup comparisons and therefore lead to an underestimation of the amount of AD pathology. Similarly, one cannot exclude that also some of the ncMCI would have converted to AD (or reverted from MCI to normal range) if followed for a longer time period. As indicated in previous studies on MCI with a follow-up of 10 years more than 80% of MCI are expected to convert to AD in the long term ([@bb0295]). Current ADNI group assignments should be therefore considered carefully and the results need to be validated using cohorts with a longer follow-up than currently available from the ADNI. However, this limitation is common to all imaging studies including not pathologically proven AD patients and control subjects. Furthermore, as we compare all subgroups exactly to the same control group, the potential inclusion of control subjects with preclinical AD would affect all comparisons in the same way without introducing a bias towards a specific subgroup. Also the finding of only a very weak link between TTC and symptom severity in our cohort requires careful interpretation. TTC is only a crude and general estimate of cognitive function. It is therefore likely that some more specific cognitive tests might be more closely related to disease progression as indicated by TTC. It is important to note that all differential results reported in our study are detected by comparing all patient subgroups to the same control group. We therefore provide only indirect evidence for between-subgroup differences. In contrast, the direct subgroup comparisons were not significant. These findings therefore need to be validated in future studies by direct comparisons of patient subgroups using larger data sets than currently available from ADNI and preferably in longitudinal study designs.

In our study we observed a slight decrease in sensitivity of FDG-PET at later as compared to earlier AD stages. We interpret this effect as an interaction of pathophysiology with the PVE correction performed in our study. However, this effect might be also caused by methodical artifacts, e.g. due to intensity normalisation (cerebellar metabolism is known to decline in AD) or due to increasing inaccuracy of PVE correction caused by increasing cortical atrophy and associated problems with accurate MRI segmentation.

Our results have potential implications for the selection of biomarkers, MCI staging and for treatment evaluation. While FDG-PET appears to be a more sensitive biomarker of disease progression at the MCI stage, structural differences as measured by sMRI seem to be more strongly linked to the current global cognitive state, potentially reflecting irreversible damage. Therefore, we suggest that for treatment evaluation it may be crucial to use both structural and functional biomarkers.
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![MRI and FDG-PET results for the comparison of three groups of AD patients, MCI converters (cMCI) and non-converters (ncMCI) split by age compared to the same group of control subjects. a) MRI (blue: atrophy) and FDG-PET (red: hypometabolism) results plotted onto an averaged brain. Overlapping results are displayed in violet. Results for differently aged subgroups are separated by rows. Results for different clinical groups are separated by columns. Cortical hypometabolism in ncMCI patients was restricted to the right hemisphere. In contrast, in both other groups the results were much more symmetric however with more extensive changes in the left hemisphere. b) Number of significant voxels (p = 0.001 uncorrected at voxel level and p = 0.05 FWE corrected at cluster level) detected in each comparison in FDG-PET (red) and MRI (blue). AD Alzheimer's disease, FDG-PET \[18F\]fluorodeoxyglucose positron emission tomography, FWE family-wise error, MCI Mild Cognitive Impairment, MRI structural magnetic resonance imaging, \* indicates a significant difference between modalities within the condition, \*\* indicates a significant difference to all other conditions within the modality. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr1){#f0005}

![MRI and FDG-PET results for the comparison of three groups of AD patients, MCI converters (cMCI) and non-converters (ncMCI) split by symptom severity compared to the same group of control subjects. a) MRI (blue: atrophy) and FDG-PET (red: hypometabolism) results plotted onto an averaged brain. Overlapping results are displayed in violet. Results for differently affected subgroups are separated by rows. Results for different clinical groups are separated by columns. b) Number of significant voxels (p = 0.001 uncorrected at voxel level and p = 0.05 FWE corrected at cluster level) detected in each comparison in FDG-PET (red) and MRI (blue). AD Alzheimer\'s disease, FDG-PET \[18F\]fluorodeoxyglucose positron emission tomography, FWE family-wise error, MCI Mild Cognitive Impairment, MRI structural magnetic resonance imaging, \* indicates a significant difference between modalities within the condition, \*\* indicates a significant difference to all other conditions within the modality. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr2){#f0010}

![MRI and FDG-PET results for the comparison of three subgroups of MCI converters split by time to conversion compared to the same group of control subjects. a) MRI (blue: atrophy) and FDG-PET (red: hypometabolism) results plotted onto an averaged brain. Overlapping results are displayed in violet. Results for different subgroups are separated by columns. b) Number of significant voxels (p = 0.001 uncorrected at voxel level and p = 0.05 FWE corrected at cluster level) detected in each comparison in FDG-PET (red) and MRI (blue). AD Alzheimer\'s disease, FDG-PET \[18F\]fluorodeoxyglucose positron emission tomography, FWE family-wise error, MCI Mild Cognitive Impairment, MRI structural magnetic resonance imaging, \* indicates a significant difference between modalities within the condition, \*\* indicates a significant difference to all other conditions within the modality. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr3){#f0015}

![Significant age and MMSE related positive correlations observed in MRI (blue) and FDG-PET (red) in AD patients, MCI converters (cMCI) and MCI non-converters (ncMCI). AD Alzheimer\'s disease, FDG-PET \[18F\]fluorodeoxyglucose positron emission tomography, MCI Mild Cognitive Impairment, MRI structural magnetic resonance imaging. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr4){#f0020}

###### 

Subject group characteristic.

                         Controls     AD           MCI con      MCI noncon   ANOVA (df,F,P)
  ---------------------- ------------ ------------ ------------ ------------ ----------------
  Number                 79           80           65           64           --
  Male/Female            41/38        40/40        41/24        38/26        --
  Age (years)            75.8 ± 4.9   75.7 ± 7.0   75.1 ± 6.9   75.6 ± 6.8   3,0.1,.938
  Age range (min--max)   62--87       55--88       58--88       60--87       --
  MMSE (score)           28.7 ± 1.6   23.6 ± 2.2   26.8 ± 1.8   27.5 ± 1.7   3,109.9,\<.001

Mean ± standard deviation. AD Alzheimer's disease, ANOVA analysis of variance, con converters, MCI mild cognitive impairment, MMSE Mini Mental State Examination, noncon non-converters.

###### 

Subgroup characteristics for AD patients.

  Age evaluation                                                       
  ----------------------------- ------------ ------------ ------------ ----------------
  Number                        25           25           25           --
  Male/Female                   12/13        12/13        14/11        --
  Age (years)                   69.2 ± 3.7   75.6 ± 1.3   82.2 ± 3.0   2,131.6,\<.001
  Age range (min--max)          59--73       73--78       78--87       --
  MMSE (score)                  23.8 ± 2.1   23.8 ± 2.1   23.5 ± 2.3   2,0.2,.833
                                                                       
  Symptom severity evaluation                                          
                                                                       
                                High MMSE    Mean MMSE    Low MMSE     ANOVA (df,F,p)
  Number                        25           25           25           --
  Male/Female                   11/14        14/11        12/13        --
  Age (years)                   75.4 ± 6.2   75.5 ± 5.8   76.5 ± 7.0   2,0.2,0.791
  MMSE (score)                  26.0 ± 0.7   23.9 ± 0.9   21.0 ± 0.7   2,257.9,\<.001

Mean ± standard deviation. AD Alzheimer's disease, ANOVA analysis of variance, MCI mild cognitive impairment, MMSE Mini Mental State Examination.

###### 

Subgroup characteristics for MCI converters.

  Age evaluation                                                         
  ------------------------------- ------------ ------------ ------------ ----------------
  Number                          21           21           21           --
  Male/Female                     11/10        14/7         14/7         --
  Age (years)                     67.9 ± 4.1   75.6 ± 1.8   82.0 ± 2.9   2,109.2,\<.001
  Age range (min--max)            58--72       73--78       79--88       --
  MMSE (score)                    27.3 ± 1.9   26.9 ± 1.6   26.1 ± 1.7   2,2.8,.068
  TTC (months)                    21.1 ± 7.7   19.4 ± 9.8   18.0 ± 7.8   2,0.7,.493
                                                                         
  Symptom severity evaluation                                            
                                                                         
                                  High MMSE    Mean MMSE    Low MMSE     ANOVA (df,F,p)
  Number                          21           21           21           --
  Male/Female                     14/7         15/6         11/10        --
  Age (years)                     72.6 ± 6.8   76.3 ± 5.0   76.5 ± 7.5   2,2.4,.1
  MMSE (score)                    28.8 ± 0.7   26.9 ± 0.6   24.8 ± 0.6   2,218.6,\<.001
  TTC (months)                    21.4 ± 8.6   20.3 ± 8.2   16.9 ± 8.4   2,1.7,.193
                                                                         
  Time to conversion evaluation                                          
                                                                         
                                  24 months    18 months    12 months    ANOVA (df,F,p)
  Number                          15           15           15           --
  Male/Female                     10/5         9/6          8/7          --
  Age (years)                     76.3 ± 5.1   76.8 ± 7.7   76.8 ± 5.9   2,0.0,.973
  MMSE (score)                    27.1 ± 1.7   26.7 ± 1.8   26.5 ± 1.8   2,0.4,.701

Mean ± standard deviation. ANOVA analysis of variance, MCI mild cognitive impairment, MMSE Mini Mental State Examination.

###### 

Subgroup characteristics for MCI non-converters.

  Age evaluation                                                       
  ----------------------------- ------------ ------------ ------------ -------------------
  Number                        21           21           21           --
  Male/Female                   11/10        13/8         13/8         --
  Age (years)                   68.0 ± 4.6   75.7 ± 1.8   82.6 ± 2.4   2,111.2,. \< .001
  Age range (min--max)          60--74       74--79       79--87       --
  MMSE (score)                  27.7 ± 1.4   28.1 ± 1.5   26.9 ± 1.8   2,3.1,.051
                                                                       
  Symptom severity evaluation                                          
                                                                       
                                High MMSE    Mean MMSE    Low MMSE     ANOVA (df,F,p)
  Number                        21           21           21           --
  Male/Female                   13/8         12/9         12/9         --
  Age (years)                   75.1 ± 6.2   75.4 ± 6.8   75.7 ± 7.3   2,0.0,.957
  MMSE (score)                  29.2 ± 0.5   27.7 ± 0.5   25.6 ± 1.8   2,105.4,\<.001

Mean ± standard deviation. ANOVA analysis of variance, MCI mild cognitive impairment, MMSE Mini Mental State Examination.
